Compare with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs CADILA HEALTHCARE - Comparison Results

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES CADILA HEALTHCARE ALKEM LABORATORIES/
CADILA HEALTHCARE
 
P/E (TTM) x 21.9 24.5 89.4% View Chart
P/BV x 5.3 4.3 123.0% View Chart
Dividend Yield % 0.9 0.8 114.2%  

Financials

 ALKEM LABORATORIES   CADILA HEALTHCARE
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-20
CADILA HEALTHCARE
Mar-20
ALKEM LABORATORIES/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs2,720352 772.1%   
Low Rs1,660207 804.0%   
Sales per share (Unadj.) Rs697.9139.2 501.2%  
Earnings per share (Unadj.) Rs96.111.8 817.0%  
Cash flow per share (Unadj.) Rs117.318.6 631.5%  
Dividends per share (Unadj.) Rs25.003.50 714.3%  
Dividend yield (eoy) %1.11.3 91.1%  
Book value per share (Unadj.) Rs515.2101.4 508.4%  
Shares outstanding (eoy) m119.571,023.74 11.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.12.0 156.4%   
Avg P/E ratio x22.823.7 95.9%  
P/CF ratio (eoy) x18.715.0 124.1%  
Price / Book Value ratio x4.32.8 154.2%  
Dividend payout %26.029.8 87.4%   
Avg Mkt Cap Rs m261,879286,033 91.6%   
No. of employees `00014.313.4 106.9%   
Total wages/salary Rs m15,05524,145 62.4%   
Avg. sales/employee Rs Th5,822.610,632.7 54.8%   
Avg. wages/employee Rs Th1,050.51,801.2 58.3%   
Avg. net profit/employee Rs Th802.0898.5 89.3%   
INCOME DATA
Net Sales Rs m83,444142,531 58.5%  
Other income Rs m1,0421,139 91.5%   
Total revenues Rs m84,486143,670 58.8%   
Gross profit Rs m14,73424,198 60.9%  
Depreciation Rs m2,5286,965 36.3%   
Interest Rs m6513,418 19.0%   
Profit before tax Rs m12,59814,954 84.2%   
Minority Interest Rs m0288 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,1053,198 34.5%   
Profit after tax Rs m11,49312,044 95.4%  
Gross profit margin %17.717.0 104.0%  
Effective tax rate %8.821.4 41.0%   
Net profit margin %13.88.5 163.0%  
BALANCE SHEET DATA
Current assets Rs m54,96087,154 63.1%   
Current liabilities Rs m32,43382,694 39.2%   
Net working cap to sales %27.03.1 862.8%  
Current ratio x1.71.1 160.8%  
Inventory Days Days8071 111.4%  
Debtors Days Days7294 76.9%  
Net fixed assets Rs m32,710133,236 24.6%   
Share capital Rs m2391,024 23.3%   
"Free" reserves Rs m61,368102,733 59.7%   
Net worth Rs m61,607103,757 59.4%   
Long term debt Rs m1,59232,146 5.0%   
Total assets Rs m99,433236,866 42.0%  
Interest coverage x20.45.4 378.9%   
Debt to equity ratio x00.3 8.3%  
Sales to assets ratio x0.80.6 139.5%   
Return on assets %12.26.5 187.1%  
Return on equity %18.711.6 160.7%  
Return on capital %21.013.7 152.7%  
Exports to sales %19.10-   
Imports to sales %3.00-   
Exports (fob) Rs m15,917NA-   
Imports (cif) Rs m2,483NA-   
Fx inflow Rs m16,06152,752 30.4%   
Fx outflow Rs m2,48314,504 17.1%   
Net fx Rs m13,57838,248 35.5%   
CASH FLOW
From Operations Rs m5,85125,054 23.4%  
From Investments Rs m-7,414-10,123 73.2%  
From Financial Activity Rs m792-10,942 -7.2%  
Net Cashflow Rs m-7313,989 -18.3%  

Share Holding

Indian Promoters % 66.9 74.8 89.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 8.3 398.8%  
FIIs % 0.0 5.9 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 11.0 -  
Shareholders   68,381 44,069 155.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   PROCTER & GAMBLE HEALTH  STERLING BIOTECH  TORRENT PHARMA  VENUS REMEDIES  CIPLA  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Bloodbath on Dalal Street: 6 Reasons Why Sensex Nosedived 1,939 Points Today(Closing)

Indian share markets witnessed a sharp sell-off today and ended deep in the red.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Feb 26, 2021 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS